Imunon, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMNN research report →
Range $10 – $10
Price Chart
About the company
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications.
- CEO
- Stacy R. Lindborg
- IPO
- 1999
- Employees
- 20
- HQ
- Lawrenceville, NJ, US
Get TickerSpark's AI analysis on IMNN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.47M
- P/E
- -0.14
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.28
- EV/EBITDA
- -0.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -349.02%
- ROIC
- -154.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-14,650,694
- Net Income
- $-14,495,000+22.2%
- EPS
- $-6.83+67.6%
- OCF Growth
- +26.3%
- FCF Growth
- +24.9%
- 52W High
- $4.35
- 52W Low
- $0.49
- 50D MA
- $1.08
- 200D MA
- $2.05
- Beta
- 2.08
- RSI (14)
- 25
- Avg Volume
- 150.63K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Imunon said it kept OVATION-3 enrollment on track, strengthened external validation for IMNN-001, and took more steps to focus capital on its ovarian cancer program while still facing a going-concern cash need.· November 12, 2026
- OVATION-3 enrollment was described as tracking to plan, with 18 sites selected, 9 active and 9 in start-up at quarter-end.
- Management said enrollment averaged about 0.4 patients per active site per month versus a planning assumption of about 0.3.
- The company highlighted new validation from the National Cancer Institute CRADA, independent monitoring committees, and R&D Day presentations.
- Imunon also sold ThermoDox rights to a partner and exchanged debt for preferred stock to narrow focus and reduce dilution.
- Cash remains tight: the company said there is substantial doubt about its ability to continue as a going concern and that additional capital is required to complete OVATION-3.
For third quarter 2026, research and development expenses were $1.8 million, versus $1.9 million in the same period last year, and general and administrative expenses were $1.7 million versus $1.6 million last year. Nonoperating expenses were $302,000, compared with de minimis nonoperating income a year ago. Net loss available to common shareholders was $3.8 million, or $0.64 per share, versus $3.4 million, or $1.16 per common share, in the third quarter of 2025. Net cash used in operating activities was $3.2 million for the quarter and $10.2 million for the first nine months of 2026. At September 30, 2026, cash and cash equivalents were $4.0 million, plus $5.0 million of restricted cash. Forward-looking operating milestones include 50% enrollment in OVATION-3 in the first quarter of 2028, completion of enrollment in the first quarter of 2029, and the first preplanned interim analysis currently estimated for the first quarter of 2030.
Stacy Lindborg emphasized that the company’s priorities are now centered on executing OVATION-3, deepening data validation, and keeping resources pointed at the lead program. She framed the quarter as one where prior assertions around data strength, enrollment, and validation moved to evidence, citing the NCI CRADA, independent DMC reviews, and the R&D Day presentations. Her tone was confident about the program but explicit that Imunon still needs more capital to fully execute the Phase III plan.
Josh Blacher said the quarter’s spending was essentially stable year over year, with R&D at $1.8 million and G&A at $1.7 million. He also noted $302,000 of nonoperating expenses tied largely to financing costs and a net loss of $3.8 million, or $0.64 per share. On liquidity, he reported $4.0 million of cash and cash equivalents plus $5.0 million of restricted cash, and reiterated the going-concern warning disclosed in filings.
Analysts focused on whether renewed IL-12 activity in the field helps validate Imunon’s approach; management said the biology was never the problem and that IMNN-001 has already overcome the historic safety issues that limited prior IL-12 efforts. Another question centered on how far current resources can go on site activation: Stacy said the company needs additional capital to complete the trial and activate all 50 planned sites, and that capital raising is underway. On ThermoDox, management said there is no deadline for the buyer’s $2.5 million financing, and the deal remains contingent on that step.
The bullish case is that OVATION-3 enrollment appears to be proceeding at or above plan, with active-site productivity cited at about 0.4 patients per site per month. Management also pointed to multiple independent validations, no new safety concerns, and growing outside interest in IL-12, all of which support confidence in IMNN-001. The NCI CRADA and ThermoDox divestiture may also be viewed as capital-efficient ways to expand optionality while concentrating on the lead asset.
The biggest risk remains financing: the company said it needs additional capital to complete OVATION-3 and activate all planned sites, and it disclosed substantial doubt about its ability to continue as a going concern. The interim analysis and eventual readout are still years away based on current timelines, so execution risk remains high. ThermoDox value is also contingent on another company’s financing, development, and commercialization success, and Imunon’s current cash balance is low.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.3%
- Shares Outstanding
- 6.49M
- Float Shares
- 5.15M
of shares held by institutions
23 13F filers
Buy/sell ratio 4.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 270.50K | ▲ 125.73K |
| Vanguard Capital Management LLC | 46.97K | 0 |
| Geode Capital Management, LLC | 41.10K | ▲ 9.47K |
| Vanguard Group Inc | 37.05K | ▲ 13.75K |
| Nvest Financial, LLC | 26.29K | ▲ 26.29K |
| Virtu Financial LLC | 17.46K | ▲ 17.46K |
| State Street Corp | 15.83K | ▲ 15.83K |
| Vanguard Fiduciary Trust Co | 13.27K | 0 |
| Hrt Financial LP | 11.70K | ▲ 11.70K |
| Northern Trust Corp | 10.34K | 0 |
| Tower Research Capital LLC (Trc) | 5.60K | ▲ 1.64K |
| Blackrock, Inc. | 4.46K | 0 |
Held by 6 ETFs
Biggest fund positions in IMNN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Braun Donald P | other | 11,746 |
| Nov 6, 26 | Dentzer James E | other | 13,166 |
| Nov 6, 26 | Pellizzari Christine A | other | 13,166 |
| Nov 6, 26 | Fritz Frederick J. | other | 13.166 |
| Nov 6, 26 | Faller Douglas Vincent | other | 1,596 |
| Nov 6, 26 | Lindborg Stacy | other | 3,804 |
| Nov 6, 26 | Tardugno Michael H | other | 9,969 |
| Oct 23, 26 | Tardugno Michael H | other | 6,821 |
| Oct 23, 26 | Lindborg Stacy | other | 2,603 |
| Oct 23, 26 | Faller Douglas Vincent | other | 26,741 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMNN coverage
Recent articles, reports, and earnings notes.
No research on IMNN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMNN report →Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 12
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
globenewswire.com · Nov 6
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
globenewswire.com · Nov 2
IMUNON Announces Strategic Sale of ThermoDox®
globenewswire.com · Oct 21
IMUNON to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 8
IMUNON Converts $1.2 Million of Debt-to-Equity
globenewswire.com · Sep 29
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
globenewswire.com · Sep 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.